A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient's data

基于真实患者数据的流行病学研究,对糖尿病患病率进行混合预测成本效益分类

阅读:1

Abstract

The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classification results to forecast cost/benefit ratio in diabetes mellitus patients along with prevalence. In total 108 invasive and non-invasive medical features are considered from 251 patients for assessment, and the real-time data are gathered from Pakistan over a time span of June 2017 to April 2018. The results indicate that J48 classifiers achieved the best accuracy of (99.28%), whereas, error rate (0.08%), Kappa stats, PRC, and MCC are (0.98%), precision, recall, and F-matrix are (0.99%). In addition, true positive rate is (0.99%) and false positive is (0.08%). The regression forecast decision indicates blood pressure and glucose level are key features for diabetes. The cost/benefit matrix indicates two predictions for positive test with accuracy (66.68%) and (30.60%), and key attributes with total Gain (118.13%). The study confirmed the proposed prediction is practical for screening of diabetes mellitus patients at the initial stage without invasive medical tests and found effectual in the early diagnosis of diabetes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。